{
  "drug_name": "Acetazolamide",
  "url": "https://wikem.org/wiki/Acetazolamide",
  "scraped_at": "2026-01-10T07:46:38.322520",
  "sections": {
    "General": {
      "text": "Type: Carbonic anhydrase inhibitor\nDosage Forms: PO/IV\nCommon Trade Names: Diamox",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Glaucoma": {
          "text": "Closed-angle Glaucoma:\n500mg PO/IV, followed by 125-250mg PO q4h\n500mg PO q12h (sustained release)\nOpen-angle Glucoma:\n250mg-1g PO/IV QD\n500mg PO q12h (sustained release)",
          "tables": []
        },
        "Treatment": {
          "text": "500-1000mg extended release PO QD\nContinue treatment for 48 hours or longer if necessary",
          "tables": []
        },
        "Prophylaxis": {
          "text": "125mg PO BID\n[1]\nStart 24hr before ascent and continue for the first 48hrs at peak altitude",
          "tables": []
        },
        "CHF-associated_Edema": {
          "text": "250-375mg PO qAM\n5mg/kg",
          "tables": []
        },
        "Drug-induced_Edema": {
          "text": "250-375mg PO qAM",
          "tables": []
        },
        "Epilepsy": {
          "text": "8-30mg/kg/day PO QD\nDo not exceed 30mg/kg/day or 1g/day",
          "tables": []
        },
        "Off-label_use": {
          "text": "Familial periodic paralysis; Hydrocephalus, normal-pressure; Idiopathic intracranial hypertension; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Glaucoma": {
      "text": "Closed-angle Glaucoma:\n500mg PO/IV, followed by 125-250mg PO q4h\n500mg PO q12h (sustained release)\nOpen-angle Glucoma:\n250mg-1g PO/IV QD\n500mg PO q12h (sustained release)",
      "subsections": {
        "Treatment": {
          "text": "500-1000mg extended release PO QD\nContinue treatment for 48 hours or longer if necessary",
          "tables": []
        },
        "Prophylaxis": {
          "text": "125mg PO BID\n[1]\nStart 24hr before ascent and continue for the first 48hrs at peak altitude",
          "tables": []
        },
        "CHF-associated_Edema": {
          "text": "250-375mg PO qAM\n5mg/kg",
          "tables": []
        },
        "Drug-induced_Edema": {
          "text": "250-375mg PO qAM",
          "tables": []
        },
        "Epilepsy": {
          "text": "8-30mg/kg/day PO QD\nDo not exceed 30mg/kg/day or 1g/day",
          "tables": []
        },
        "Off-label_use": {
          "text": "Familial periodic paralysis; Hydrocephalus, normal-pressure; Idiopathic intracranial hypertension; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Acute_altitude_sickness": {
      "text": "",
      "subsections": {
        "Treatment": {
          "text": "500-1000mg extended release PO QD\nContinue treatment for 48 hours or longer if necessary",
          "tables": []
        },
        "Prophylaxis": {
          "text": "125mg PO BID\n[1]\nStart 24hr before ascent and continue for the first 48hrs at peak altitude",
          "tables": []
        },
        "CHF-associated_Edema": {
          "text": "250-375mg PO qAM\n5mg/kg",
          "tables": []
        },
        "Drug-induced_Edema": {
          "text": "250-375mg PO qAM",
          "tables": []
        },
        "Epilepsy": {
          "text": "8-30mg/kg/day PO QD\nDo not exceed 30mg/kg/day or 1g/day",
          "tables": []
        },
        "Off-label_use": {
          "text": "Familial periodic paralysis; Hydrocephalus, normal-pressure; Idiopathic intracranial hypertension; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "CHF-associated_Edema": {
      "text": "250-375mg PO qAM\n5mg/kg",
      "subsections": {
        "Drug-induced_Edema": {
          "text": "250-375mg PO qAM",
          "tables": []
        },
        "Epilepsy": {
          "text": "8-30mg/kg/day PO QD\nDo not exceed 30mg/kg/day or 1g/day",
          "tables": []
        },
        "Off-label_use": {
          "text": "Familial periodic paralysis; Hydrocephalus, normal-pressure; Idiopathic intracranial hypertension; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Drug-induced_Edema": {
      "text": "250-375mg PO qAM",
      "subsections": {
        "Epilepsy": {
          "text": "8-30mg/kg/day PO QD\nDo not exceed 30mg/kg/day or 1g/day",
          "tables": []
        },
        "Off-label_use": {
          "text": "Familial periodic paralysis; Hydrocephalus, normal-pressure; Idiopathic intracranial hypertension; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Epilepsy": {
      "text": "8-30mg/kg/day PO QD\nDo not exceed 30mg/kg/day or 1g/day",
      "subsections": {
        "Off-label_use": {
          "text": "Familial periodic paralysis; Hydrocephalus, normal-pressure; Idiopathic intracranial hypertension; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Off-label_use": {
      "text": "Familial periodic paralysis; Hydrocephalus, normal-pressure; Idiopathic intracranial hypertension; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "",
      "subsections": {
        "Epilepsy_2": {
          "text": "<12 years: safety and efficacy not established\n>12 years: 8-30mg/kg/day PO QD",
          "tables": []
        },
        "Treatment_2": {
          "text": "<12 years: safety and efficacy not established\n>12 years: 500-1000mg PO QD",
          "tables": []
        },
        "Prophylaxis_2": {
          "text": "2.5mg/kg/dose (maximum 125mg/dose) PO every 12 hours\n[2]\nStart 24hr before ascent and continue for the first 48hrs at peak altitude",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Epilepsy_2": {
      "text": "<12 years: safety and efficacy not established\n>12 years: 8-30mg/kg/day PO QD",
      "subsections": {
        "Treatment_2": {
          "text": "<12 years: safety and efficacy not established\n>12 years: 500-1000mg PO QD",
          "tables": []
        },
        "Prophylaxis_2": {
          "text": "2.5mg/kg/dose (maximum 125mg/dose) PO every 12 hours\n[2]\nStart 24hr before ascent and continue for the first 48hrs at peak altitude",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Acute_altitude_sickness_2": {
      "text": "",
      "subsections": {
        "Treatment_2": {
          "text": "<12 years: safety and efficacy not established\n>12 years: 500-1000mg PO QD",
          "tables": []
        },
        "Prophylaxis_2": {
          "text": "2.5mg/kg/dose (maximum 125mg/dose) PO every 12 hours\n[2]\nStart 24hr before ascent and continue for the first 48hrs at peak altitude",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: C\nLactation risk\n: Safe\nRenal Dosing\nAdult: CrCl 10-50: give q12h; CrCl<10: avoid use; HD/PD: not defined\nPediatric: CrCl 10-50: give q12h; CrCl<10: avoid use, HD/PD: not defined\nHepatic Dosing\nAdult: contraindicated in significant impairment/cirrhosis\nPediatric: contraindicated in significant impairment/cirrhosis\nGeriatric: Refer to adult dosing. Oral: Initial doses should begin at the low end of the dosage range.",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nhypokalemia\nhyponatremia\nacidosis, hyperchloremic\nacidosis, metabolic\nadrenal insufficiency\ncirrhosis\nhepatic disease, severe\nrenal disease, severe\nglaucoma, angle-closure (long-term use)\ncaution if hypersensitivity to sulfonamides\ncaution if ASA treatment, high-dose\ncaution if hepatic impairment\ncaution if pulmonary impairment\ncaution if diabetes mellitus\ncaution if gout\ncaution if elderly patients",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "metabolic acidosis\nelectrolyte imbalance\nanaphylaxis\nerythema multiforme\nStevens-Johnson syndrome\ntoxic epidermal necrolysis\nhepatic necrosis\nhepatic impairment\nagranulocytosis\nanemia, hemolytic\nmyelosuppression\nleukopenia\npancytopenia\nblood dyscrasias\nthrombocytopenic purpura\nseizures\nparalysis, flaccid\ncrystalluria\nnephrolithiasis",
          "tables": []
        },
        "Common": {
          "text": "fatigue\nmalaise\ntaste change\nanorexia\nnausea/vomiting\nparethesia\ndiarrhea\npolyuria\nelectrolyte disorders\ntinnitus\nhearing changes\nmyopia\ndrowsiness\nconfusion\nuticaria\nrash\nphotosensitivity\nglucosuria\nhematuria\nmelena",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "metabolic acidosis\nelectrolyte imbalance\nanaphylaxis\nerythema multiforme\nStevens-Johnson syndrome\ntoxic epidermal necrolysis\nhepatic necrosis\nhepatic impairment\nagranulocytosis\nanemia, hemolytic\nmyelosuppression\nleukopenia\npancytopenia\nblood dyscrasias\nthrombocytopenic purpura\nseizures\nparalysis, flaccid\ncrystalluria\nnephrolithiasis",
      "subsections": {
        "Common": {
          "text": "fatigue\nmalaise\ntaste change\nanorexia\nnausea/vomiting\nparethesia\ndiarrhea\npolyuria\nelectrolyte disorders\ntinnitus\nhearing changes\nmyopia\ndrowsiness\nconfusion\nuticaria\nrash\nphotosensitivity\nglucosuria\nhematuria\nmelena",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "fatigue\nmalaise\ntaste change\nanorexia\nnausea/vomiting\nparethesia\ndiarrhea\npolyuria\nelectrolyte disorders\ntinnitus\nhearing changes\nmyopia\ndrowsiness\nconfusion\nuticaria\nrash\nphotosensitivity\nglucosuria\nhematuria\nmelena",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 10-15h\nMetabolism:  CYP450\nExcretion: urine (100% unchanged)\nMechanism of Action: inhibits carbonic anhydrase",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "References": {
      "text": "Acetazolamide injection [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals, Inc; October 2015.",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}